| Identification | Back Directory | [Name]
3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- | [CAS]
1922098-69-8 | [Synonyms]
3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- | [Molecular Formula]
C23H19ClF2N2O3 | [MOL File]
1922098-69-8.mol | [Molecular Weight]
444.86 |
| Chemical Properties | Back Directory | [Boiling point ]
657.1±55.0 °C(Predicted) | [density ]
1.40±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:107.0(Max Conc. mg/mL);240.52(Max Conc. mM)
Ethanol:89.0(Max Conc. mg/mL);200.06(Max Conc. mM) | [form ]
Solid | [pka]
13.69±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor[1]. CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis[2]. | [in vivo]
CCG-222740 (oral gavage; 100 mg/kg/day for 7 days) significantly reduces α-SMA levels in the pancreas of caerulein-stimulated KC mice[1].
| Animal Model: | KC mice (LSL-KrasG12D/+; Pdx-1-Cre) of age at 9 weeks[1] | | Dosage: | 100?mg/kg | | Administration: | Oral gavage; daily; for 7 days | | Result: | Reduced α-SMA levels in the pancreas of caerulein-stimulated KC mice.
|
| [References]
[1] Leal AS, et al. The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Sci Rep. 2019 May 8;9(1):7072. DOI:10.1038/s41598-019-43430-0
[2] Yu-Wai-Man C, et al. Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis. Sci Rep. 2017 Mar 31;7(1):518. DOI:10.1038/s41598-017-00212-w |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|